Clover Health Investments Corp (CLOV) concluded trading on Wednesday at a closing price of $3.08, with 4.24 million shares of worth about $13.05 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -11.49% during that period and on June 04, 2025 the price saw a loss of about -0.65%. Currently the company’s common shares owned by public are about 388.51M shares, out of which, 382.10M shares are available for trading.
Stock saw a price change of -1.60% in past 5 days and over the past one month there was a price change of -8.06%. Year-to-date (YTD), CLOV shares are showing a performance of -2.22% which increased to 180.00% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $0.90 but also hit the highest price of $4.87 during that period. The average intraday trading volume for Clover Health Investments Corp shares is 6.06 million. The stock is currently trading -8.62% below its 20-day simple moving average (SMA20), while that difference is down -10.97% for SMA50 and it goes to -13.83% lower than SMA200.
Clover Health Investments Corp (NASDAQ: CLOV) currently have 388.51M outstanding shares and institutions hold larger chunk of about 20.90% of that.
The stock has a current market capitalization of $1.57B and its 3Y-monthly beta is at 1.93. It has posted earnings per share of -$0.05 in the same period. It has a debt-to-equity ratio of 0.00. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for CLOV, volatility over the week remained 1.39% while standing at 4.10% over the month.
Stock’s fiscal year EPS is expected to rise by 36.85% while it is estimated to increase by 67.05% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Craig Hallum on December 17, 2024 offering a Buy rating for the stock and assigned a target price of $6 to it. Coverage by UBS stated Clover Health Investments Corp (CLOV) stock as a Neutral in their note to investors on October 07, 2024, suggesting a price target of $4 for the stock. On February 02, 2022, Cowen Upgrade their recommendations, while on February 02, 2022, Canaccord Genuity Initiated their ratings for the stock with a price target of $6. Stock get a Mkt perform rating from SVB Leerink on January 19, 2022.
